Skip to main content

Advertisement

SpringerLink
Log in

Nonalcoholic Fatty Liver Disease and Extra-hepatic Malignancy

  • Fatty Liver Disease (SA Harrison and J George, Section editors)
  • Published:
Current Hepatology Reports Aims and scope Submit manuscript

Abstract

Nonalcoholic fatty liver disease (NAFLD) has risen to become the most common cause of chronic liver disease in Western nations in concert with rising rates of obesity. The majority of patients with NAFLD meet criteria for the metabolic syndrome and are often found to have insulin resistance (IR) or frank diabetes along with increased rates of cardiovascular disease, overall mortality, and primary hepatocellular carcinoma (HCC). The association of NAFLD with cancer specifically is an area of more recent investigation with the majority of data coming indirectly from population based studies linking obesity and a variety of extra-hepatic malignancies. Research specifically linking NAFLD with cancer has been limited to colorectal adenomas and colorectal cancer (CRC), with the majority of data showing an increased prevalence of both in NAFLD populations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Targher G, Day C, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. NEJM. 2010;363:1341–50.

    Article  CAS  PubMed  Google Scholar 

  2. Dunn W, Xu R, et al. Suspected nonalcoholic fatty liver disease and mortality risk in a population-based cohort study. Am J Gastroenterol. 2008;103:2263–71.

    Article  PubMed Central  PubMed  Google Scholar 

  3. Korenblat K, Fabbrini E, Mohammed B, Klein S. Liver, muscle, and adipose tissue insulin action is directly related to intrahepatic triglyceride content in obese subjects. Gastroenterology. 2008;134:1369–75.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  4. Williams CD, Stengel J, Asike MI, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology. 2011;140:124–31.

    Article  PubMed  Google Scholar 

  5. Chalasani N et al. The diagnosis and management of Non-alcoholic fatty liver disease: practice guideline by the american association for the study of liver diseases, american college of gastroenterology, and the american gastroenterological association. Hepatology. 2012;55:2005–23.

    Article  PubMed  Google Scholar 

  6. Tiniakos D, Vos M, Brunt E. Nonalcoholic fatty liver disease: pathology and pathogenesis. Annu Rev Pathol. 2010;5:145–71.

    Article  CAS  PubMed  Google Scholar 

  7. Kershaw E, Flier J. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab. 2004;89:2548–56.

    Article  CAS  PubMed  Google Scholar 

  8. Van Der Poorten D et al. Visceral fat: a key mediator of steatohepatitis in metabolic liver disease. Hepatology. 2008;48:449–57.

    Article  PubMed  Google Scholar 

  9. Executive Summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285:2486–97.

    Google Scholar 

  10. Day CP, James OF. Steatohepatitis: a tale of two “hits”? Gastroenterology. 1998;114:842–5.

    Article  CAS  PubMed  Google Scholar 

  11. Tilg H, Moschen A. Evolution of inflammation in nonacloholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology. 2010;52:1836–46.

    Article  CAS  PubMed  Google Scholar 

  12. Flegal K, Carroll M, Kit B, Ogden C. Prevalence of obesity and trends in the distribution of body mass index among US adults. J Am Med Assoc. 2012;307:491–7.

    Article  Google Scholar 

  13. Hossain P, Kawar B, El Nahas M. Obesity and diabetes in the developing world – a growing challenge. NEJM. 2007;356:213–15.

    Article  CAS  PubMed  Google Scholar 

  14. Cheal K, Abbasi F, et al. Relationship to insulin resistance of the adult treatment panel III diagnostic criteria for identification of the metabolic syndrome. Diabetes. 2004;53:195–200.

    Article  Google Scholar 

  15. Hamaguchi M, Kojima T, et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med. 2005;143:722–8.

    Article  CAS  PubMed  Google Scholar 

  16. Ahmed M, Byrne C. In: Packard CJ, editor. Metabolic syndrome, diabetes, & CHD risk. The year in lipid disorders. Oxford: Clinical Publishing; 2007. p. 3–26.

    Google Scholar 

  17. Younossi Z, Stepanova M, et al. Changes in the prevalence of the most common causes of chronic liver diseases in the united states from 1988–2008. Clin Gastroenterol Hepatol. 2011;9:524–30.

    Article  PubMed  Google Scholar 

  18. Jemal A, Bray F, et al. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.

    Article  PubMed  Google Scholar 

  19. Vucenik I, Stains J. Obesity and cancer risk: evidence, mechanisms, and recommendations. Ann NY Acad Sci. 2012;1271:37–43. Excellent review focused on the mechanisms linking obesity and cancer.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  20. Calle E, Rodriquez C, Walker-Thurmond K, Thun M. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. Adults. NEJM. 2003;348:1625–38.

    Article  PubMed  Google Scholar 

  21. Hunter DJ, Willet WC. Nutrition and breast cancer. Cancer Causes Control. 1996;7:56–8.

    Article  CAS  PubMed  Google Scholar 

  22. Potter JD. Nutrition and colorectal cancer. Cancer Causes Control. 1996;7:127–46.

    Article  CAS  PubMed  Google Scholar 

  23. Chow W-H, Blot WJ, Vaughan TL, et al. Body mass index and risk of adenocarcinoma of the esophagus and gastric cardia. J Natl Cancer Inst. 1998;90:150–5.

    Article  CAS  PubMed  Google Scholar 

  24. Strom BL, Soloway RD, Rios-Dalenz JL, et al. Risk factors for gallbladder cancer; an international collaborative case–control study. Cancer. 1995;76:1747–56.

    Article  CAS  PubMed  Google Scholar 

  25. Silverman DT, Swanson CA, Gridley G, et al. Dietary and nutritional factors and pancreatic cancer; a case–control study based on direct interviews. J Natl Cancer Inst. 1998;90:1710–9.

    Article  CAS  PubMed  Google Scholar 

  26. Pais R, Silaghi H, Silaghi C, Rusu M, Dumitrascu D. Metabolic syndrome and risk of subsequent colorectal cancer. World J Gastroenterol. 2009;15:5141–8.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  27. Ahmed R, Schmitz KH, et al. The metabolic syndrome and risk of incident colorectal cancer. Cancer. 2006;107:28–36.

    Article  PubMed  Google Scholar 

  28. Trevisan M, Liu J, et al. Markers of insulin resistance and colorectal cancer mortality. Cancer Epidemiol Biomarkers Prev. 2001;10:937–41.

    CAS  PubMed  Google Scholar 

  29. Colangelo L, Gapstur S, et al. Colorectal cancer mortality and factors related to the insulin resistance syndrome. Cancer Epidemiol Biomarkers Prev. 2002;11:385–91.

    PubMed  Google Scholar 

  30. Kabat G, Kim M, et al. A longitudinal study of the metabolic syndrome and risk of colorectal cancer in postmenopausal women. Eur J Cancer Prev. 2012;21:326–32.

    Article  CAS  PubMed  Google Scholar 

  31. Aleksandrova K, Boeing H, et al. Metabolic syndrome and risks of colon and rectal cancer: the European prospective investigation into cancer and nutrition study. Cancer Prev Res. 2011;4:1873–83.

    Article  CAS  Google Scholar 

  32. Chen J. Multiple signal pathways in obesity-associated cancer. Obes Rev. 2011;12:1063–70.

    Article  PubMed  Google Scholar 

  33. Lyon C, Law R, Hsueh W. Minireview: adiposity, inflammation, and atherogenesis. Endocrinology. 2003;144:2195–200.

    Article  CAS  PubMed  Google Scholar 

  34. Huang X, Chen J. Obesity, the PI3K/Akt signal pathway and colon cancer. Obes Rev. 2009;10:610–6.

    Article  CAS  PubMed  Google Scholar 

  35. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer. 2009;9:798–809.

    Article  CAS  PubMed  Google Scholar 

  36. Paz-Filho G, Lim E, Wong M, Licinio J. Associations between adipokines and obesity-related cancer. Front Biosci. 2011;16:1634–50.

    Article  CAS  Google Scholar 

  37. Howard J, Pidgeon G, Reynolds J. Leptin and gastrointestinal malignancies. Obes Rev. 2010;11:863–74.

    Article  CAS  PubMed  Google Scholar 

  38. Gao J, Tian J, Lv Y, et al. Leptin induces functional activation of cyclooxygenase 2 through JAK2/STAT3, MAPK/ERK, and PI3K/AKT pathways in human endometrial cancer cells. Cancer Sci. 2009;100:389–95.

    Article  CAS  PubMed  Google Scholar 

  39. Dalamaga M, Diakopoulos K, Mantzoros C. The role of adiponectin in cancer: a review of current evidence. Endocr Rev. 2012;33:547–94.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  40. Hui J, Hodge A, et al. Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology. 2004;40:46–54.

    Article  CAS  PubMed  Google Scholar 

  41. Wong V, Wong L, et al. Genetic polymorphisms of adiponectin and tumor necrosis factor-alpha and nonalcoholic fatty liver disease in Chinese people. J Gastroenterol Hepatol. 2008;23:914–21.

    Article  CAS  PubMed  Google Scholar 

  42. Unger R, Scherer P. Gluttony, sloth and the metabolic syndrome: a roadmap to lipotoxicity. Trends Endocrinol Metab. 2010;21:345–52.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  43. Yamaji T, Iwasaki M, Sasazuki S, Tsugane S. Interaction between adiponectin and leptin influences the risk of colorectal adenoma. Cancer Res. 2010;70:5430–7.

    Article  CAS  PubMed  Google Scholar 

  44. Wei E, Giovannucci E, Fuchs S, Willett W, Mantzoros C. Low plasma adiponectin levels and risk of colorectal cancer in men: a prospective study. J Natl Cancer Inst. 2005;97:1688–94.

    Article  CAS  PubMed  Google Scholar 

  45. Ferroni P, Palmirotta R, et al. Prognostic significance of adiponectin levels in non-metastatic colorectal cancer. Anticancer Res. 2007;27:483–9.

    CAS  PubMed  Google Scholar 

  46. Rose D, Komninou D, Stephenson G. Obesity, adipocytokines, and insulin resistance in breast cancer. Obes Rev. 2004;5:153–65.

    Article  CAS  PubMed  Google Scholar 

  47. Stattin P, Lukanova A, et al. Obesity and colon cancer: does leptin provide a link? Int J Cancer. 2004;109:149–52.

    Article  CAS  PubMed  Google Scholar 

  48. Taubes R. Cancer research. Unraveling the obesity-cancer connection. Science. 2012;335:28,30–32.

    Google Scholar 

  49. Renehan A, Frystyk J, Flyvbjer A. Obesity and cancer risk: the role of insulin-IGF axis. Trends Endocrinol Metab. 2006;17:328–36.

    Article  CAS  PubMed  Google Scholar 

  50. Grimberg A, Cohen P. Role of insulin-like growth factors and their binding proteins in growth control and carcinogenesis. J Cell Physiol. 2000;183:1–9.

    Article  CAS  PubMed  Google Scholar 

  51. Warren R, Yuan H, et al. Induction of vascular endothelial growth factor by insulin-like growth factor 1 in colorectal carcinoma. J Biol Chem. 1996;271:29483–8.

    Article  CAS  PubMed  Google Scholar 

  52. Sandhu M, Dunger D, Giovannucci E. Insulin, insulin-like growth factor- I (IFG-1), IGF binding proteins, their biologic interactions, and colorectal cancer. J Natl Cancer Inst. 2002;94:972–80.

    Article  CAS  PubMed  Google Scholar 

  53. Williams A, Collard T, et al. Increased p53-dependent apoptosis by the insulin-like growth factor binding proein IGFBP-3 in human colonic adenoma-derived cells. Cancer Res. 2000;60:22–7.

    CAS  PubMed  Google Scholar 

  54. Giovannucci E, Pollak M, et al. A prospective study of plasma insulin-like growth factor-1 and binding protein-3 and risk of colorectal neoplasia in women. Cancer Epidemiol Biomarkers Prev. 2000;9:345–9.

    CAS  PubMed  Google Scholar 

  55. Hwang S, Cho Y, et al. Relationship of non-alcohol fatty liver disease to colorectal adenomatous polyps. J Gastroenterol Hepatol. 2010;25:562–7.

    Article  CAS  PubMed  Google Scholar 

  56. Stadlmayr A, Aigner E, et al. Nonalcoholic fatty liver disease: an independent risk factor for colorectal neoplasia. J Intern Med. 2011;270:41–9. Large study demonstrating increased prevalence of colonic adenomas and CRC in NAFLD population.

    Article  CAS  PubMed  Google Scholar 

  57. Lee Y, Lim Y, Park H. Colorectal neoplasms in relation to non-alcoholic fatty liver disease in Korean women: a retrospective cohort study. J Gastroenterol Hepatol. 2012;27:91–5.

    Article  CAS  PubMed  Google Scholar 

  58. Huang K, Leu H, et al. Patients with nonalcoholic fatty liver disease have higher risk of colorectal adenoma after negative baseline colonoscopy. Colorectal Dis. 2013;15:830–5.

    Article  PubMed  Google Scholar 

  59. Wong V, Wong G, et al. High prevalence of colorectal neoplasm in patients with non-alcoholic steatohepatitis. Gut. 2011;60:829–36.

    Article  PubMed  Google Scholar 

  60. Touzin NT, Bush K, Williams CD, Harrison SA. Prevalence of colonic adenomas in patients with nonalcoholic fatty liver disease. Ther Adv Gastroenterol. 2011;4:169–76.

    Article  Google Scholar 

  61. Min YW, Yun HS, Chang WI, et al. Influence of non-alcoholic fatty liver disease on the prognosis of patients with colorectal cancer. Clin Res Hepatol Gastroenterol. 2012;36:78–83.

    Article  PubMed  Google Scholar 

  62. Armstrong MJ, Adams LA, Canbay A, Syn WK. Extra-hepatic complications of nonalcoholic fatty liver disease. Hepatology. 2014. doi:10.1002/hep.26717. Excellent overview of extra-hepatic complications of NAFLD (including colon adenomas and CRC).

    Google Scholar 

Download references

Compliance with Ethics Guidelines

ᅟ

Conflict of Interest

Dustin M. Albert and Dawn M. Torres declare no conflicts of interest.

Human and Animal Rights and Informed Consent

All studies by Dustin M. Albert and Dawn M. Torres involving human subjects were performed after approval by the appropriate Institutional Review Boards. Written informed consent was obtained from all participants.

Author information

Authors and Affiliations

  1. Department of Medicine, Walter Reed National Military Medical Center, Bethesda, MD, USA

    Dustin M. Albert

  2. Division of Gastroenterology, Department of Medicine, Walter Reed National Military Medical Center, Bethesda, MD, 20889, USA

    Dawn M. Torres

Authors
  1. Dustin M. Albert
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dawn M. Torres
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dawn M. Torres.

Additional information

Disclaimer

The view(s) expressed herein are those of the author(s) and do not reflect the official policy or position of Walter Reed Military Medical Center, the U.S. Army Medical Department, the U.S. Army Office of the Surgeon General, the Department of the Army, Department of Defense or the U.S. Government.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Albert, D.M., Torres, D.M. Nonalcoholic Fatty Liver Disease and Extra-hepatic Malignancy. Curr Hepatology Rep 13, 106–112 (2014). https://doi.org/10.1007/s11901-014-0213-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11901-014-0213-y

Keywords

Search

Navigation